论文部分内容阅读
目的探讨分析细胞因子诱导的杀伤(CIK)细胞联合多西紫杉醇化疗对晚期转移性乳腺癌患者的影响。方法选取2012年3月至2013年9月治疗的52例晚期转移性乳腺癌患者作为研究对象,采用随机数字法将其分为观察组和对照组各26例。对照组给予表阿霉素~+多西紫杉醇常规化疗治疗,观察组给予CIK细胞联合多西紫杉醇化疗治疗。观察两组治疗疗效、临床症状改善情况以及治疗前后细胞免疫表型变化情况。结果观察组总有效率为76.92%,明显高于对照组的42.31%(χ~2=6.470,P<0.05)。治疗前两组患者的临床症状评分及细胞免疫表型比较差异无统计学意义(P均>0.05);而治疗后观察组患者在疲倦乏力、局部疼痛、失眠盗汗上的临床临床症状评分均较治疗前降低(P均<0.01),且低于对照组治疗后(P均<0.01)。治疗后观察组患者细胞免疫表型中CD3~+、自然杀伤(NK)细胞、自然杀伤性T(NKT)细胞的百分率及CD3~+/CD4~+、CD4~+/CD8~+比值均高于对照组(P均<0.01),CD3~+/CD8~+比值低于对照组(P<0.01)。结论 CIK细胞联合多西紫杉醇化疗治疗晚期转移性乳腺癌效果较好,安全性和可行性较高。
Objective To investigate the effect of cytokine-induced killer (CIK) cells combined with docetaxel chemotherapy on patients with advanced metastatic breast cancer. Methods Fifty-two patients with advanced metastatic breast cancer who were treated from March 2012 to September 2013 were selected as study subjects, and randomly divided into observation group and control group with 26 cases in each group. Control group given epirubicin ~ + docetaxel conventional chemotherapy, the observation group given CIK cells combined with docetaxel chemotherapy. The curative effect, the improvement of clinical symptoms and the changes of cellular immunophenotype before and after treatment were observed. Results The total effective rate in the observation group was 76.92%, which was significantly higher than that in the control group (42.31%, χ ~ 2 = 6.470, P <0.05). There was no significant difference in clinical symptom scores and cellular immunophenotype between the two groups before treatment (P> 0.05). After treatment, the scores of clinical symptoms in fatigue, local pain and insomnia were significantly lower in observation group (P <0.01), and lower than that of the control group after treatment (all P <0.01). After treatment, the percentage of CD3 ~ +, NK cells, NKT cells and the ratio of CD3 ~ + / CD4 ~ + and CD4 ~ + / CD8 ~ + were all higher in observation group In the control group (all P <0.01), the ratio of CD3 ~ + / CD8 ~ + was lower than that of the control group (P <0.01). Conclusion CIK cells combined with docetaxel chemotherapy for advanced metastatic breast cancer better effect, safety and feasibility.